A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION Lung12)

When lung cancer is found at an early stage, surgery is often the best way to remove the cancer cells. However, even after successful surgery, there's always a chance that some tiny cancer cells might be left behind, which could cause the cancer to return later. This is why doctors sometimes recommend additional treatment after surgery, known as 'adjuvant therapy', to try and kill any remaining cancer cells and reduce the risk of the cancer coming back.

This study, called TROPION Lung12, is focusing on a specific type of early-stage lung cancer called Stage I adenocarcinoma non-small cell lung cancer. Researchers are particularly interested in patients whose cancer has certain characteristics that might make it more likely to return. These characteristics include a positive 'ctDNA' test result, which looks for tiny fragments of cancer DNA in the blood, or other ‘high-risk pathological features’ seen when the cancer tissue is examined under a microscope after surgery.

The main goal of this study is to find out if new treatments are better than current standard care at stopping the cancer from returning. Patients in the study will be divided into groups to receive either a new drug combination (Datopotamab Deruxtecan with Rilvegostomig), Rilvegostomig on its own, or treatments that are considered standard care. Researchers will carefully track how long patients remain free from their cancer and also look at overall survival and how treatments affect daily life and well-being. This research could lead to new, more effective ways to help people stay cancer-free after surgery.